A Paradox and Alan Rein: Distinguished Retrovirologist Retires from the HIV DRP

The Fort Detrick gate hours will change beginning Friday, April 10. The new hours were recently provided by the U.S. Army Garrison (USAG), Fort Detrick. NCI will continue to work with the USAG to address questions that may arise. Note that no changes have been made for facilities outside of the Fort Detrick campus (e.g., the Advanced Technology Research Facility).

The 19th Annual Spring Research Festival (SRF), sponsored by the National Interagency Confederation for Biological Research (NICBR), will be held May 4–7, at the same location as last year: just off Porter Street, in the back parking lot of Building 1507 (Odom Fitness Center).

The additional funding requested for Frederick National Laboratory for Cancer Research (FNLCR) in the Fiscal 2016 Bypass Budget was $25 million, or approximately 3.5 percent of the total additional funding request of $715 million.

The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.

Platinum Publications are selected from articles by NCI at Frederick scientists published in 42 prestigious science journals. This list represents articles published during the time period shown above, as generated from PubMed. Articles designated as Platinum Highlights are noteworthy articles selected by Dr. Craig Reynolds, associate director, National Cancer Institute, from among the most recently published Platinum Publications.